Prelude Therapeutics Inc
Prelude Therapeutics Inc logo
PRLD

Prelude Therapeutics Inc (PRLD)

$6.674.71%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$6.44
Day's Range
$6.85
$3.87
52-Week Range
$15.57
1 month return4.78%
3 month return10.53%
1 year return55.42%
5 year return75.69%

Company Information

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.
OrganizationPrelude Therapeutics Inc
Employees120
CEODr. Krishna Vaddi D.V.M., Ph.D.
IndustryHealth Technology

Analyst Recommendation

based on 4 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 4 Wall street analysts offering stock ratings for Prelude Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 43.93%

Current

$6.67

Target

$9.6

Recommendation Trend

Based on 4 analyst

Current1M Ago3M Ago
Buy
4
7
8
Hold
0
4
3
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
307.2M
Book Value
$4.57
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.58
Wall Street Target Price
9.6

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
1.5
Enterprise Value
103.7M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-0.85

Technicals

Beta
0.33
50 Day MA
6.89
200 Day MA
6.58

Institutional Holdings

Orbimed Advisors, LLC

32.85%

Baker Bros Advisors LP

21.16%

FMR Inc

8.99%

UBS Asset Mgmt Americas Inc

5.06%

Vanguard Group Inc

1.88%

Hillhouse Capital Advisors, Ltd.

1.22%

Discover more

Frequently Asked Questions

What is Prelude Therapeutics Inc share price today?

Can Indians buy Prelude Therapeutics Inc shares?

How can I buy Prelude Therapeutics Inc shares from India?

Can Fractional shares of Prelude Therapeutics Inc be purchased?

What are the documents required to start investing in Prelude Therapeutics Inc stocks?

What are today’s High and Low prices of Prelude Therapeutics Inc?

What are today’s traded volumes of Prelude Therapeutics Inc?

What is today’s market capitalisation of Prelude Therapeutics Inc?

What is the 52 Week High and Low Range of Prelude Therapeutics Inc?

How much percentage Prelude Therapeutics Inc is down from its 52 Week High?

How much percentage Prelude Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Prelude Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Prelude Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*